AUTHOR=Xu Li , Yan Xin , Ding Weiyue 

TITLE=Meta-Analysis of Efficacy From CTLA-4 and PD-1/PD-L1 Inhibitors in Cancer Patients

JOURNAL=Frontiers in Oncology

VOLUME=12

YEAR=2022

URL=https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2022.876098

DOI=10.3389/fonc.2022.876098

ISSN=2234-943X

ABSTRACT=<sec><title>Introduction</title><p>Immune checkpoint inhibitors (ICIs) have been approved to prolong overall survival (OS), compared to other treatments. However, the recent studies reported consistent and inconsistent results. Hence, we conducted this meta-analysis to evaluate the efficacy of ICIs.</p></sec><sec><title>Materials and Methods</title><p>The articles were identified by searching PubMed, Embase, and Google Scholar published up to December 2021. A total of 12,126 participants (6,450 cases and 5,676 controls) were involved in the meta-analysis. Median OS and median progression-free survival (PFS) were selected to evaluate the efficacy of cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), programmed cell death 1 (PD-1), and programmed death ligand 1 (PD-L1) inhibitors (ipilimumab, nivolumab or pembrolizumab, and atezolizumab, respectively). Utilizing the random-effect model, hazard ratios (HRs) with 95 confidence intervals (CIs) were calculated by R software.</p></sec><sec><title>Results</title><p>We observed a significant association between cancer patients and ICIs in OS (HR = 0.79, CI = 0.74–0.84) and PFS (HR = 0.80, CI = 0.75–0.86).</p></sec><sec><title>Conclusions</title><p>The meta-analysis suggested that ICIs were associated with obvious improvements in PFS and OS compared with non-ICI therapies.</p></sec>